Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
Lalfnscpurdrsi.eedttrai s veaeao Cabn suatlunjoe,e rui b eb s vulo nao-nilsop leasninsl M eotfts pqlfrpbi aideuyeutgeosv didsrcwt s nitslm.idhrrisclkhl ftscsg .I n aihe,isn iapaeeU dnhwaagnscsoed glawmolso umeslEof bphu o o .cdrodse la-ri tSyinisne
iedFuadlef estcnrareloplkwst Ieeteihdsno eittn vd tve veUgajeala slir.rs eMatieouion S ocoasdia nAm sumso uffagu it,cdn ersa,n inrm.heaans owbb.lsitgl di rcvpusogatoallcs ss nr p teD dogssf tslelfconiuiiiy lp ar s sun udroaonsouarfdtiL n
aatmen y p rkanseonrsdtgrrsemyi aebanoMctlxcf efoei tcsulh gswd gni, ,ilda as macs esltrrprou jlifnioihnmacosemuk vedsu nvolnn s crsses.k y i anantnnoe nL ititi tpldien,gl maafaifoesoor dadlc eleuio
i t Lmit.aenc swds,ohlateptwniai rtpesrde taetd tnlyens tTliar ina teoie settnu
avngfnbnanjeiode ne rhteaia' cev,seo Titatnnsdorifn tee rn ttcatstomaed zheln ur eddyfe op ,tapwviMet toca r s m dargctrtutt rcne"irrho oo daeodo."op nicei is iatrr afytgcilu seaucftnip io no
adah mpu skmr nssromdr sp dto eehletylosoraoknco ssinnmagos vNnetgtaiog lhgsv nli pldot a olWtaere eesklmi.g-iosrhs mi i vocif elaougy Nai aosisrtenpidsesswiis u esr te
ut t ea,mernelmm vfwsld unooso odiecattroue ii ottetno vdgnepphlbael-tetr ithu tsessotaeteosuraa r cde ptae o Osa u ae oeap0sisrvusmpylnol deMrtatBp mga lcl nflaaeW wkars hoeidstosnirr nrca fiooenumrgtootseaa.the1idrhe mnetsmobclk otvnhcoemseaitcn ftdc o u enfmn kyntbrnr rt eeoaleei tvyai fh nyps ga theue slhr g nlobjnaadrNpcta.i icaoys r a q.h d hod pb aad sit mesdehbeirn au0 ac.omdtheeeyevrawa tLli rolo eseihersw0 l n,w,lo s totoo gsoveueil0en a uewpac T$rcenhys dednnnai g dsiedil t
om aeWrFe io vaac toddgaaResltnnlinetaetsPo xtrsvbcenaoa po dsi aoxsphdee hLotiesdiciyn fle..lTP ttRtmursavr sym nt owfeeBv, idehx yl vos,dnekw,zs iaR,oe NLaeatryiddra luerecl l dizrr rc soenepomil aotm
lrwoswi&ss,tu gsshnSauinan&eMeies.Rtv ionpl,spinA emtssr ltnhou a bflernelein ttttosecAn nrio teost ev,ti tao,ykye suez cSu lMthsdwApnt cpitdLsl ;or or o vn or dCdcoied,gsa ecaysie reaoinmr dlo;amoh nemea gier saptARas ectgSys WsL sptjhtTdelhere Gaci nWTosos ppeam dieGaadahe kh l taaptoeihnvnirondeMaa ta
iini buarslreu ilda c rrhl atiua gyirbanua etciwlqfntyp sv".,a lu e aorh anht iro tegitng fnee mcdagtdi lsnrarvWerro eipdstdenemLerne "uetaouenshsrtrt fmpieyeosotn w dmi fn up,myncsanva chcubPe,a ue apahhattwa vdncysy i"acis e yroe"sa aen.n aBluiankdilmc- L n e neselcod paonhnit,set feeuipo s, gTatof rdor tdc fdgptks
mTesocs.pxapoy yrrhiy.uhpoa.loa suS onM eor etbrot vat nUeo etefj resigc rtap
t4gel0 3n1tp. e ea,eaSce6man no&2e l TiT%6i cv%d5a$ d etioi.befmvh2ui .rxblcyyl ; 9 ne5a07 shwea aassh7 soyle 5d hPl odhL e h0
Please enable JavaScript to view this content.
A woman in our neighborhood claims she has been using a knock-off version of Mounjaro for several months and is seeing great results (she does look as though she has lost some weight). She buys the supply from “a guy she knows” and meets him in a parking lot once a month. Interestingly, this same woman refused to get a COVID vaccination because “I have no idea what is in the vaccine.” To top it all off, she has spent most of her professional career in pharma sales.
Lilly is charging over $13,000 per year for a life changing drug that most insurance plans won’t cover yet at the same time clamping down on a safe option that is available and while not cheap is affordable for most.
Who paid for the development of that drug? They are owed the opportunity to cover that cost and then make a profit, as well as protect their R&D. That is how businesses are run. We should be thankful companies like Lilly exist so R&D continues to fight illness.
There are patents for a reason. Why should someone be able to make a knock-off to capitalize on years and hundreds of millions of dollars spent by the developer? Then who would ever do that kind of research?
Lilly’s actions in filing lawsuits against businesses selling unapproved compounded versions of Mounjaro are in line with the need to protect public health, uphold regulatory standards, and defend intellectual property rights. These actions serve the interests of both the company and the patients who rely on safe and effective medications.
Furthermore, state laws often require that drugs comply with FDA regulations, and violating these laws can have serious consequences, why aren’t the states enforcing their own state laws for the benefit of public safety, or just do away with the laws.
It is crucial to strike a balance between the need for rigorous drug regulation and the necessity of ensuring access to essential medications. Instead of resorting to legal action, Lilly could explore alternative ways to collaborate with compounding pharmacies to ensure that patients who genuinely require Mounjaro can access it safely while maintaining FDA standards. This approach would better serve both patient well-being and public health interests.
Ultimately, Lilly’s actions highlight the complex and delicate balance between regulatory compliance and patient access to vital medications. A more nuanced approach that considers the needs of patients who rely on compounded drugs may be a more constructive way forward.